Acute heparin-induced thrombocytopenia type II during cardiopulmonary bypass

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 14, Issue 3, 2000, Pages 300-303

  Koster, Andreas ^b   Crystal, George J ^b   Kuppe, Herrmann ^b   Mertzlufft, Fritz ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b NONE

Author keywords

Ecarin clotting time; Protamine; Recombinant hirudin; White clots

Indexed keywords

HEPARIN; NADROPARIN;

AGED; AORTA CLAMPING; ARTICLE; CARDIOPULMONARY BYPASS; CASE REPORT; DRUG MEGADOSE; EXTRACORPOREAL OXYGENATION; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REACTION ANALYSIS; THROMBOCYTOPENIA;

EID: 0034047718     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/cr.2000.5847     Document Type: Article

References (15)

1. Slaughter TF, Greenberg CS: Heparin-associated thrombocytopenia and thrombosis - implications for perioperative management. Anesthesiology 87:667-675, 1997
2. Blakeman B: Management of heparin-induced thrombocytopenia: A cardiovascular surgeon's perspective. Semin Hematol 36:37-41, 1999 (suppl 1)
3. Bauer TL, Arepaly G, Konkele BA, et al: Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95:1242-1246, 1997
4. Shorten GD, Comunale ME: Heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 10:521-530, 1996
5. Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med 101:502-507, 1996
6. Koster A, Kuppe H, Hetzer R, et al: Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 89:777-780, 1998
7. Greinacher A, Völpel H, Janssens U, et al: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 99:73-80, 1999
8. Pötzsch B, Hund S, Madlener K, et al: Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time. Thromb Haemost 77:920-925, 1997
9. Koster A, Kuppe H, Mertzlufft F: Cardiopulmonary bypass with recombinant hirudin in patients with heparin-induced thrombocytopenia type.II: A synopsis of 19 cases. Br J Anaesth 82:35(A.116), 1999 (suppl 1)
10. Greinacher A, Amiral J, Dummel V, et al: Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 34:381-385, 1994
11. Newman PM, Swanson RL, Chong BH: Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low-molecular-weight heparin and heparinoid. Thromb Haemost 80:292-297, 1998
12. Warkentin TE: Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 10:249-258, 1996
13. Weitz JI, Hudoba M, Massel D, et al: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86:385-391, 1990
14. Warkentin TE, Hayward CPM, Boshkov LK, et al: Sera from patients with heparin-induced thrombocytopenia generate plateletderived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84:3691-3699, 1994
15. Bang NU: Hirudin and hirudin-mimetic peptides: A promising group of antithrombotic agents. Am Coll Cardiol Curr J Rev 2:43-45, 1993